Literature DB >> 35986085

Prognostic significance of pathogenic variants in BRCA1, BRCA2, ATM and PALB2 genes in men undergoing hormonal therapy for advanced prostate cancer.

Hiroko Kimura1, Kei Mizuno1, Masaki Shiota2, Shintaro Narita3, Naoki Terada4, Naohiro Fujimoto5, Keiji Ogura6, Shotaro Hatano6, Yusuke Iwasaki7, Nozomi Hakozaki7, Satoshi Ishitoya6, Takayuki Sumiyoshi1, Takayuki Goto1, Takashi Kobayashi1, Hidewaki Nakagawa8, Toshiyuki Kamoto4, Masatoshi Eto2, Tomonori Habuchi3, Osamu Ogawa1, Yukihide Momozawa7, Shusuke Akamatsu9,10.   

Abstract

BACKGROUND: The prognostic significance of germline variants in homologous recombination repair genes in advanced prostate cancer (PCa), especially with regard to hormonal therapy, remains controversial.
METHODS: Germline DNA from 549 Japanese men with metastatic and/or castration-resistant PCa was sequenced for 27 cancer-predisposing genes. The associations between pathogenic variants and clinical outcomes were examined. Further, for comparison, DNA from prostate biopsy tissue samples from 80 independent patients with metastatic PCa were analysed.
RESULTS: Forty-four (8%) patients carried germline pathogenic variants in one of the analysed genes. BRCA2 was most frequently altered (n = 19), followed by HOXB13 (n = 9), PALB2 (n = 5) and ATM (n = 5). Further, the BRCA1, BRCA2, PALB2 and ATM variants showed significant association with a short time to castration resistance and overall survival (hazard ratio = 1.99 and 2.36; 95% CI, 1.15-3.44 and 1.23-4.51, respectively), independent of other clinical variables. Based on log-rank tests, the time to castration resistance was also significantly short in patients with BRCA1, BRCA2, PALB2 or ATM somatic mutations and TP53 mutations.
CONCLUSIONS: Germline variants in BRCA1, BRCA2, PALB2 or ATM are independent prognostic factors of the short duration of response to hormonal therapy in advanced PCa.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Year:  2022        PMID: 35986085     DOI: 10.1038/s41416-022-01915-2

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   9.075


  42 in total

1.  Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  C Parker; E Castro; K Fizazi; A Heidenreich; P Ost; G Procopio; B Tombal; S Gillessen
Journal:  Ann Oncol       Date:  2020-06-25       Impact factor: 32.976

2.  Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.

Authors:  Kim N Chi; Neeraj Agarwal; Anders Bjartell; Byung Ha Chung; Andrea J Pereira de Santana Gomes; Robert Given; Álvaro Juárez Soto; Axel S Merseburger; Mustafa Özgüroğlu; Hirotsugu Uemura; Dingwei Ye; Kris Deprince; Vahid Naini; Jinhui Li; Shinta Cheng; Margaret K Yu; Ke Zhang; Julie S Larsen; Sharon McCarthy; Simon Chowdhury
Journal:  N Engl J Med       Date:  2019-05-31       Impact factor: 91.245

3.  Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer.

Authors:  Andrew J Armstrong; Arun A Azad; Taro Iguchi; Russell Z Szmulewitz; Daniel P Petrylak; Jeffrey Holzbeierlein; Arnauld Villers; Antonio Alcaraz; Boris Alekseev; Neal D Shore; Francisco Gomez-Veiga; Brad Rosbrook; Fabian Zohren; Shunsuke Yamada; Gabriel P Haas; Arnulf Stenzl
Journal:  J Clin Oncol       Date:  2022-04-14       Impact factor: 50.717

4.  Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.

Authors:  Karim Fizazi; NamPhuong Tran; Luis Fein; Nobuaki Matsubara; Alfredo Rodriguez-Antolin; Boris Y Alekseev; Mustafa Özgüroğlu; Dingwei Ye; Susan Feyerabend; Andrew Protheroe; Peter De Porre; Thian Kheoh; Youn C Park; Mary B Todd; Kim N Chi
Journal:  N Engl J Med       Date:  2017-06-04       Impact factor: 91.245

5.  Integrative clinical genomics of advanced prostate cancer.

Authors:  Dan Robinson; Eliezer M Van Allen; Yi-Mi Wu; Nikolaus Schultz; Robert J Lonigro; Juan-Miguel Mosquera; Bruce Montgomery; Mary-Ellen Taplin; Colin C Pritchard; Gerhardt Attard; Himisha Beltran; Wassim Abida; Robert K Bradley; Jake Vinson; Xuhong Cao; Pankaj Vats; Lakshmi P Kunju; Maha Hussain; Felix Y Feng; Scott A Tomlins; Kathleen A Cooney; David C Smith; Christine Brennan; Javed Siddiqui; Rohit Mehra; Yu Chen; Dana E Rathkopf; Michael J Morris; Stephen B Solomon; Jeremy C Durack; Victor E Reuter; Anuradha Gopalan; Jianjiong Gao; Massimo Loda; Rosina T Lis; Michaela Bowden; Stephen P Balk; Glenn Gaviola; Carrie Sougnez; Manaswi Gupta; Evan Y Yu; Elahe A Mostaghel; Heather H Cheng; Hyojeong Mulcahy; Lawrence D True; Stephen R Plymate; Heidi Dvinge; Roberta Ferraldeschi; Penny Flohr; Susana Miranda; Zafeiris Zafeiriou; Nina Tunariu; Joaquin Mateo; Raquel Perez-Lopez; Francesca Demichelis; Brian D Robinson; Marc Schiffman; David M Nanus; Scott T Tagawa; Alexandros Sigaras; Kenneth W Eng; Olivier Elemento; Andrea Sboner; Elisabeth I Heath; Howard I Scher; Kenneth J Pienta; Philip Kantoff; Johann S de Bono; Mark A Rubin; Peter S Nelson; Levi A Garraway; Charles L Sawyers; Arul M Chinnaiyan
Journal:  Cell       Date:  2015-05-21       Impact factor: 41.582

6.  Aberrations of DNA repair pathways in prostate cancer: a cornerstone of precision oncology.

Authors:  Stergios Boussios; Elie Rassy; Sidrah Shah; Evangelia Ioannidou; Matin Sheriff; Nicholas Pavlidis
Journal:  Expert Opin Ther Targets       Date:  2021-07-08       Impact factor: 6.902

7.  Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.

Authors:  Colin C Pritchard; Joaquin Mateo; Michael F Walsh; Navonil De Sarkar; Wassim Abida; Himisha Beltran; Andrea Garofalo; Roman Gulati; Suzanne Carreira; Rosalind Eeles; Olivier Elemento; Mark A Rubin; Dan Robinson; Robert Lonigro; Maha Hussain; Arul Chinnaiyan; Jake Vinson; Julie Filipenko; Levi Garraway; Mary-Ellen Taplin; Saud AlDubayan; G Celine Han; Mallory Beightol; Colm Morrissey; Belinda Nghiem; Heather H Cheng; Bruce Montgomery; Tom Walsh; Silvia Casadei; Michael Berger; Liying Zhang; Ahmet Zehir; Joseph Vijai; Howard I Scher; Charles Sawyers; Nikolaus Schultz; Philip W Kantoff; David Solit; Mark Robson; Eliezer M Van Allen; Kenneth Offit; Johann de Bono; Peter S Nelson
Journal:  N Engl J Med       Date:  2016-07-06       Impact factor: 91.245

8.  Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.

Authors:  Maha Hussain; Joaquin Mateo; Karim Fizazi; Fred Saad; Neal Shore; Shahneen Sandhu; Kim N Chi; Oliver Sartor; Neeraj Agarwal; David Olmos; Antoine Thiery-Vuillemin; Przemyslaw Twardowski; Guilhem Roubaud; Mustafa Özgüroğlu; Jinyu Kang; Joseph Burgents; Christopher Gresty; Claire Corcoran; Carrie A Adelman; Johann de Bono
Journal:  N Engl J Med       Date:  2020-09-20       Impact factor: 91.245

9.  Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.

Authors:  Gerhardt Attard; Laura Murphy; Noel W Clarke; William Cross; Robert J Jones; Christopher C Parker; Silke Gillessen; Adrian Cook; Chris Brawley; Claire L Amos; Nafisah Atako; Cheryl Pugh; Michelle Buckner; Simon Chowdhury; Zafar Malik; J Martin Russell; Clare Gilson; Hannah Rush; Jo Bowen; Anna Lydon; Ian Pedley; Joe M O'Sullivan; Alison Birtle; Joanna Gale; Narayanan Srihari; Carys Thomas; Jacob Tanguay; John Wagstaff; Prantik Das; Emma Gray; Mymoona Alzoueb; Omi Parikh; Angus Robinson; Isabel Syndikus; James Wylie; Anjali Zarkar; George Thalmann; Johann S de Bono; David P Dearnaley; Malcolm D Mason; Duncan Gilbert; Ruth E Langley; Robin Millman; David Matheson; Matthew R Sydes; Louise C Brown; Mahesh K B Parmar; Nicholas D James
Journal:  Lancet       Date:  2021-12-23       Impact factor: 79.321

10.  Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.

Authors:  Veda N Giri; Karen E Knudsen; William K Kelly; Heather H Cheng; Kathleen A Cooney; Michael S Cookson; William Dahut; Scott Weissman; Howard R Soule; Daniel P Petrylak; Adam P Dicker; Saud H AlDubayan; Amanda E Toland; Colin C Pritchard; Curtis A Pettaway; Mary B Daly; James L Mohler; J Kellogg Parsons; Peter R Carroll; Robert Pilarski; Amie Blanco; Ashley Woodson; Alanna Rahm; Mary-Ellen Taplin; Thomas J Polascik; Brian T Helfand; Colette Hyatt; Alicia K Morgans; Felix Feng; Michael Mullane; Jacqueline Powers; Raoul Concepcion; Daniel W Lin; Richard Wender; James Ryan Mark; Anthony Costello; Arthur L Burnett; Oliver Sartor; William B Isaacs; Jianfeng Xu; Jeffrey Weitzel; Gerald L Andriole; Himisha Beltran; Alberto Briganti; Lindsey Byrne; Anne Calvaresi; Thenappan Chandrasekar; David Y T Chen; Robert B Den; Albert Dobi; E David Crawford; James Eastham; Scott Eggener; Matthew L Freedman; Marc Garnick; Patrick T Gomella; Nathan Handley; Mark D Hurwitz; Joseph Izes; R Jeffrey Karnes; Costas Lallas; Lucia Languino; Stacy Loeb; Ana Maria Lopez; Kevin R Loughlin; Grace Lu-Yao; S Bruce Malkowicz; Mark Mann; Patrick Mille; Martin M Miner; Todd Morgan; Jose Moreno; Lorelei Mucci; Ronald E Myers; Sarah M Nielsen; Brock O'Neil; Wayne Pinover; Peter Pinto; Wendy Poage; Ganesh V Raj; Timothy R Rebbeck; Charles Ryan; Howard Sandler; Matthew Schiewer; E Michael D Scott; Brittany Szymaniak; William Tester; Edouard J Trabulsi; Neha Vapiwala; Evan Y Yu; Charnita Zeigler-Johnson; Leonard G Gomella
Journal:  J Clin Oncol       Date:  2020-06-09       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.